skip to main
|
skip to sidebar
Blog Archives: Nov 2004 - present
Special items: Ovarian Cancer and Us blog best viewed in Firefox
Business Wire
ZW25 is Zymeworks’ lead therapeutics program and is due to begin Phase 1
clinical development in the U.S. in late August. It is a novel
bi-specific antibody, developed using the Company’s industry-leading
Azymetric™ platform, to target two different epitopes (bi-paratopic
targeting) of the human epidermal growth factor receptor 2 (HER2)
protein, which is over-expressed on the surface of many tumor types,
including a subset of breast, gastric, lung, and ovarian cancers. ZW33
is a drug-conjugated version of ZW25 currently in development in
preparation for an IND filing in early 2017.
“We are very excited with the potential of our novel engineered
bispecific antibody ZW25 and its drug conjugate ZW33, as new treatment
options for patients with ovarian cancer,” said Gordon Ng, Ph.D., Chief
Scientific Officer of Zymeworks. “We believe ZW25’s and ZW33’s multiple
differentiated mechanisms of action can be significantly more
efficacious than current HER2-directed treatments for HER2 expressing
cancers and can enhance the range of current treatments available to
these patients.”....
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.